The TGA mandate is to regulate medicines, medical devices and biological products throughout their lifecycle. The TGA is focusing on implementing changes to ensure a greater emphasis on transparency of regulatory decision-making processes, a continuing focus on business process reform and a more strategic approach to the use of information technology to support regulatory operations.

• Expert review of medicines and medical devices regulation
  The Review was conducted by a panel of three independent experts: Emeritus Professor Lloyd Sansom AO, Mr Will Delaat AM and Professor John Horvath AO
• The Business Improvement Program
  The TGA introduced the Business Improvement Program (BIP) to make our information and communications technologies better
• TGA Reforms: a blueprint for TGA's future
  The blueprint was released on 8 December 2011 in response to several major reviews of therapeutic goods regulation that were undertaken in 2010 and 2011
  • Advertising regulatory framework - options for reform
    In June 2010, a review of the advertising arrangements for therapeutic goods other than prescription medicines was initiated
  • Complementary medicines regulatory reforms
    These reforms are part of the TGA reforms: A blueprint for TGA's future and address the recommendations of the Auditor-General's Report on Therapeutic Goods Regulation: Complementary Medicines
  • Medical devices reforms
    A series of medical device regulatory reforms increasing the rigour of pre-market assessment of higher risk medical devices, to assure the quality, safety and performance of these devices
  • Medicine labelling and packaging review
    Consultation on recommendations to change the presentation of information on the labels and packages of medicines
  • Streamlined Submission Process project (prescription medicines)
    In early 2009, the TGA commenced a significant program of business process reforms (BPR program) for the regulation of prescription medicines in Australia